Claes Axäng

Claes Axäng has a diverse work experience spanning several roles and companies. Claes most recently worked at Bavarian Nordic as the Director of R&D and CSPV QA. Before that, they served as the Director of Quality and Compliance at ICON plc. Prior to joining ICON, Claes worked at PRA Health Sciences, where they held the positions of Director of Quality Assurance and Associate Director of Quality Assurance. Claes also gained experience as a Pharmaceutical Inspector in Pharmacovigilance at the Medical Products Agency Läkemedelsverket and as an Associate Director of R&D QA at Merck Group. Earlier in their career, Claes worked as a Senior Quality Assurance Auditor at PRA International, a Clinical Auditor II at ImClone Systems (a subsidiary of Eli Lilly and Company), and a Quality Assurance Auditor and Drug Safety Associate at PRA International. Claes also served as a Post-doc at the Max Planck Institute for Medical Research and as a Clinical Research Associate at Chiltern International. Overall, Claes Axäng possesses a wealth of knowledge and expertise in the fields of quality assurance, regulatory compliance, and pharmacovigilance.

Claes Axäng holds a Doctor of Philosophy degree (PhD) in Biosciences from Chalmers University of Technology, which they earned in 2008. Prior to this, they received a Master of Science degree (MS) in Molecular Biology from the University of Gothenburg in 2002.